Drug development consultant company Certara LP has acquired Analytica Laser, a consultancy for medicine and health technology. "We are delighted to be joining Certara, a recognized leader in model-informed drug development with an expansive portfolio of quantitative solutions, consultative impact and a broad global reach,” said Roman Casciano, general manager of Analytica Laser. “Our complementary approaches will allow us to integrate health economics and outcomes research and real-world value assessments with pharmacometrics data — delivering safety, efficacy and effectiveness insights — and providing a unique market advantage for our customers.” Analytica Laser employs quantitative methodologies and proprietary software to study and predict real-world outcomes for drug-value assessment. Leveraging evidence-based practices, the company integrates analytics, advanced pharmaco-epidemiology, pharmaco-economics, modeling and data science expertise, public health intelligence, and extensive experience to advise on pricing and market access strategy. “Achieving regulatory approval alone no longer determines a drug’s or therapy’s commercial success, or even guarantees its market launch,” said Thomas Kerbusch, president of Certara. “Today, each product must be evaluated from a value perspective by payers and health authorities in order to be placed on the formulary, factored into reimbursement rates, and put into treatment plans before it is available for health care providers to prescribe. The addition of Analytica Laser will allow us to expand our science and technology decision-support system, factoring in health economics and outcomes research, and the crucial issue of real-world value from as early as Phase 1, through the product life cycle to health technology assessment and payer decisions.” Certara aims to optimize drug development and improve health outcomes. Analytica Laser seeks to provide high-level scientific evidHTMLence of real-world value of medicines and health technologies.